

## Chemo- and stereoselective synthesis of benzocycloheptene and 1-benzoxepin derivatives as $\alpha$ -sympathomimetic and anorexigenic agents

Vishnu K. Tandon,<sup>a,\*</sup> Kunwar A. Singh,<sup>a</sup> Anoop K. Awasthi,<sup>a</sup> J. M. Khanna,<sup>b</sup> Bansi Lal<sup>c</sup> and Nitya Anand<sup>d</sup>

<sup>a</sup>Department of Chemistry, Lucknow University, Lucknow 226007, India

<sup>b</sup>Ranbaxy Laboratories, New Delhi, India

<sup>c</sup>Nicholas Piramal Laboratories, Mumbai, India

<sup>d</sup>Central Drug Research Institute, Lucknow, India

Received 4 February 2004; accepted 15 March 2004

**Abstract**—The synthesis and pharmacological evaluation of *cis*- and *trans*-6-amino-6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-ols **4a–c** and **5a–c** and *cis*- and *trans*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ols **4d–f** and **5d–f** were carried out. Chemo- and stereoselective synthesis of **5a–f** was achieved by reduction of corresponding  $\alpha$ -amino ketones **3a–f** with  $\text{LiAl}(\text{t-BuO})_3\text{H}$ . *cis*-4-Amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol **4d** and *trans*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol **5d** exhibited marked anorexigenic activity in mice at a dose of  $\text{LD}_{50}$  800 and 500 mg/kg and  $\text{ED}_{50}$  75 and 55 mg/kg, respectively, while the analog *cis*-2,3-dihydroxy-6-amino-6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-ol **8** showed typical  $\alpha$ -sympathomimetic activity.

© 2004 Elsevier Ltd. All rights reserved.

Obesity and its associated diseases are an increasing challenge in medicine.<sup>1</sup> Obesity is a worldwide health problem. It has been estimated that nearly 300,000 deaths/annually in U.S.A. are attributed to obesity.<sup>2</sup> Anorexigenic drug, sibutramine is being recently used in addition to fluoxetine, phentermine, and dexfenfluramine.<sup>3</sup>  $\alpha$ -Sympathomimetic drugs constitute phenethylamines, catecholamines, and related adrenergic amines,<sup>4</sup> which can assume a number of permissible conformations at the receptor site. Rigid analogs with severely limited permissible conformations can prove helpful in this analysis. In connection with the study of agents acting on adrenergic receptor, a new route describing chemo- and stereoselective synthesis of *cis*- and *trans*-6-amino-6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-ols **4a–c** and **5a–c** and *cis*- and *trans*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ols **4d–f** and **5d–f** is being reported. Compounds **4a–c** and **5a–c** have been shown to possess typical  $\alpha$ -sympathomimetic activity. We have carried out detailed pharmacological evalua-

tion of *cis*- and *trans*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ols **4d–f** and **5d–f**. These amino alcohols have been found to possess marked anorexigenic activity. The results of anorexigenic activity of **4d–f** and **5d–f** are shown in Table 1. Effect on blood pressure and interaction with adrenaline, histamine, and acetylcholine was studied in anesthetized (pentobarbitone 35.0 mg/kg iv) cats using 2.5 mg/kg of each compound. The anorexigenic activity was tested by measuring the reduction of milk intake in overnight fasted mice. Gross behavioral effects and acute toxicity ( $\text{ALD}_{50}$ ) of the compounds **4d–f** and **5d–f** was studied in albino mice by intraperitoneal administration of these compounds suspended in gum acacia using five animals per dose.

The compounds **4d–f** and **5d–f** in general exhibited a weak stimulant action and marked anorexigenic activity. The most marked anorexigenic activity was shown by *cis*- and *trans*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ols **4d** and **5d**. Their  $\text{LD}_{50}$  in mice is 800 and 500 mg/kg and  $\text{ED}_{50}$  is 75 and 55 mg/kg, respectively. Replacement of  $\text{R}^1$  by methyl group did not show any anorexigenic activity. Replacement of  $\text{R}^1$  by methoxy group also did not cause any anorexigenic activity in both *cis*- and *trans*-isomers. The marked anorexigenic activity

\* Corresponding author. Tel.: +91-522-2684388; fax: +91-522-23266-65; e-mail: [vishnutandon@yahoo.co.in](mailto:vishnutandon@yahoo.co.in)

**Table 1.** Anorexigenic activity of compounds **4d–f** and **5d–f**

Compounds	R	R <sup>1</sup>	ALD <sub>50</sub> mg/kg ip (in mice)	Gross effect (mice) ip	Effect on blood pressure, change in mm (duration in minutes)	Anorexigenic activity in mice, ED <sub>50</sub> mg/kg, ip
<b>4d</b>	H	H	800	Stimulation <sup>a</sup>	44 ↓ (transient)	75
<b>5d</b>	H	H	500	Stimulation	32 ↓ 40	55
<b>4e</b>	H	Me	300	Stimulation	10 ↓ (transient)	NE
<b>5e</b>	H	Me	150	Stimulation	38 ↓ 160	NE
<b>4f</b>	H	OMe	150	Stimulation	20 ↓ (transient)	NE
<b>5f</b>	H	OMe	150	Stimulation	40 ↓ (transient)	NE

NE = No effect.


<sup>a</sup> Increase in spontaneous motor activity, respiration, reactivity, tremors, and convulsions.**Table 2.** Pharmacological activity of compounds **4a–c**, **4g**, and **5a**

Compounds	R	R <sup>1</sup>	ALD <sub>50</sub> mg/kg ip (in mice)	Gross effect (mice) ip	Protection against amphetamine toxicity ED <sub>50</sub> mg/kg, pc	Effect on blood pressure, change in mm Hg (duration in minutes)
<b>4a</b>	H	H	150	Tranquilizer	73	NE
<b>4b</b>	Me	Me	150	NE	NE	NE
<b>4c</b>	OMe	OMe	150	NE	NE	NE
<b>4g</b>	OH	OH	150	Depression	NE	51 (13')
<b>5a</b>	H	H	150	NE	NE	NE

NE = No effect.


exhibited by *cis*- and *trans*-amino alcohols **4d** and **5d** refers these as lead compounds of the series.


The compounds **4a–c** and **5a–c** were evaluated for their pharmacological activity by standard methods and these are reported in Table 2. *cis*-6-Amino-6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-ol<sup>5</sup> **4a** has LD<sub>50</sub> 150 mg/kg, ip in mice. It gave protection against amphetamine toxicity (ED<sub>50</sub> 73 mg/kg, po). It showed typical effects of a tranquilizer in the EEG in rabbits. The corresponding *trans*-isomer **5a** did not show any tranquilizing activity. The reason for the activity of *cis*-isomer **4a** compared to the *trans*-isomer **5a** indicates that ephedrine configuration is necessary for activity of these compounds (Fig. 1). *cis*-2,3-Dihydroxy-6-amino-6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-ol **4g** in gross observation studies in mice LD<sub>50</sub> 150 mg/kg ip showed only slight depression and no other prominent effect. In normal anesthetized cats at a dose of 1 mg/kg iv, it caused 51 mm Hg fall of BP for 13 min. The responses to epinephrine, norepinephrine, and tyramine were potentiated by pretreatment with the compound. It showed stimulant effect on rabbit heart in vitro, which could be blocked by a β-blocker (DCI). Thus **4d** has a direct sympathomimetic effect, stimulating the α-adrenergic receptors. The corresponding *trans*-isomer **5g** did not show any

**Scheme 1.** Reagents and conditions: (a) KOEt, *n*-BuONO; (b) 10% Pd/C, H<sub>2</sub>; (c) LiAlH<sub>4</sub>, NaBH<sub>4</sub> or 10% Pd/C, H<sub>2</sub>; (d) LiAl(*t*-BuO)<sub>3</sub>H.

sympathomimetic activity. The synthesis of *trans*-6-amino-6,7,8,9-tetrahydro-5*H*-benzocyclo-hepten-5-ols **5a–c** and *trans*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ols **5d–f** and corresponding *cis*-isomer is shown in Schemes 1 and 2.

Oximino ketones **2a–f** obtained by nitrosation of the ketones **1**, on catalytic reduction in presence of 10% Pd/C gave α-amino ketones, which were converted into hydrochlorides **3a–f** by treatment with ethereal HCl. The synthetic data for compounds **2** and **3** are given in Tables 3 and 4, respectively. We have devised a new route for the synthesis of *cis*- or *trans*-amino alcohols by

**Figure 1.**



**Scheme 2.** Reagents and conditions: (a) Ac<sub>2</sub>O, MeOH; (b) benzene, fractional crystallization; (c) 10% aq NaOH.

**Table 3.** Synthetic data for compounds 2

Compounds	X	n	R	R <sup>1</sup>	Mp °C	Yield %
2a	CH <sub>2</sub>	2	H	H	127–128	60
2b	CH <sub>2</sub>	2	Me	Me	192	70
2c	CH <sub>2</sub>	2	OMe	OMe	173	73
2d	O	2	H	H	125–127	69
2e	O	2	H	Me	123–124	88
2f	O	2	H	OMe	118–119	82

**Table 4.** Synthetic data for compounds 3

Compounds	X	n	R	R <sup>1</sup>	Mp °C	Yield %
3a	CH <sub>2</sub>	2	H	H	183	90
3b	CH <sub>2</sub>	2	Me	Me	205–207	85
3c	CH <sub>2</sub>	2	OMe	OMe	168–170	88
3d	O	2	H	H	208–210	62
3e	O	2	H	Me	198–200	53
3f	O	2	H	OMe	189–190	72

**Table 5.** Synthetic data for compounds 4

Compounds	X	n	R	R <sup>1</sup>	Mp °C HCl	Yield %
4a	CH <sub>2</sub>	2	H	H	278	90
4b	CH <sub>2</sub>	2	Me	Me	292	88
4c	CH <sub>2</sub>	2	OMe	OMe	230	45
4d	O	2	H	H	260	78
4e	O	2	H	Me	252	73
4f	O	2	H	OMe	240	88

**Table 6.** Synthetic data for compounds 5

Compounds	X	n	R	R <sup>1</sup>	Mp °C	Yield %
5a	CH <sub>2</sub>	2	H	H	147–48	87
5b	CH <sub>2</sub>	2	Me	Me	178–180	90
5c	CH <sub>2</sub>	2	OMe	OMe	135	89
5d	O	2	H	H	153–154	3
5e	O	2	H	Me	148–149	92
5f	O	2	H	OMe	143–144	85

use of LiAl(*t*-BuO)<sub>3</sub>H or conversion into acetamido alcohols 6 as shown in Schemes 1 and 2. It seemed essential to devise method for exclusive synthesis of *cis*- and *trans*-isomers as reduction of  $\alpha$ -amino ketones 3a–f with LiAlH<sub>4</sub>, NaBH<sub>4</sub>, or 10% Pd/C, H led to mixture of *cis*- and *trans*-amino alcohols 4a–f and 5a–f in varied proportions, which were difficult to separate.  $\alpha$ -Amino ketones 3 on reduction with LiAl(*t*-BuO)<sub>3</sub>H in THF gave exclusively *trans*-amino alcohols 5 (Table 5). *cis*-Amino alcohols 4 were synthesized by conversion of mixture of 4 and 5 obtained by reduction of  $\alpha$ -amino ketones 3 into acetamido alcohols 6a–f and 7a–f. *cis*-Acetamido alcohols 6 could be isolated as insoluble part by fractional crystallization with benzene from mixture of 6a–f and 7a–f. Compound 6 on hydrolysis with aqueous NaOH resulted in isolation of *cis*-amino alcohols 4a–f (Table 6).<sup>5</sup> Thus both *cis*- and *trans*- isomers can be synthesized in pure form according to Schemes 1 and 2. The structures of these compounds were elucidated on the basis of <sup>1</sup>H NMR spectra.

In conclusion we have devised new route for synthesis of *cis*- and *trans*-amino alcohols 4a–f and 5a–f<sup>6,7</sup> having marked pharmacological activity. Both compounds 4d and 5d are lead compounds for anorexigenic activity in mice whereas 4a is a lead compound as tranquilizer and 4g has  $\alpha$ -sympathomimetic activity.

### Acknowledgements

The authors are thankful to the Regional Sophisticated Instrumentation Centre, CDRI, Lucknow for elemental analysis, spectral data, and pharmacological activity. This work was supported by a research grant from University Grants Commission of India.

### References and notes

- Nisoli, E.; Carruba, M. O. *J. Endocrinol. Invest.* **2002**, *25*, 905.
- James, W. P. T.; Astrup, A.; Finer, N. *Lancet* **2000**, 356, 2119.
- Welman, P. J.; Jones, S. L.; Miller, D. K. *Pharmacol. Biochem. Behav.* **2003**, *75*, 103.
- Hoffmann, B. B.; Lefkowitz, R. J. In *The Pharmacological Basis of Therapeutics*, 9th ed.; Goodman, Gilman, Eds.; McGraw-Hill: U.S.A., 1996; pp 232–233.
- Khanna, J. M.; Bolger, J.; Anand, N. *Indian J. Chem.* **1969**, *7*, 550.
- General procedure for stereoselective synthesis of 5*: LiAl(*t*-BuO)<sub>3</sub>H (0.47 g, 15 mmol) was added to a solution of

**3a–f** (10 mmol) in anhydrous THF (5 mL) with stirring at room temperature. The reaction mixture was stirred at 30 °C for 12 h diluted with water and extracted with CHCl<sub>3</sub>. The CHCl<sub>3</sub> extract was dried over Na<sub>2</sub>SO<sub>4</sub> and filtrate concentrated in vacuo. The residue was crystallized from CHCl<sub>3</sub>–*n*-C<sub>6</sub>H<sub>12</sub> to give crystalline **5a–f**. For example, *trans*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol (**5d**) yield 83%; mp 153–154 °C; IR 3350 (OH) and 3300 (NH)/cm; <sup>1</sup>H NMR δ 2.02 (br h, 3H, OH, NH<sub>2</sub> exchangeable by D<sub>2</sub>O), 2.75 (m, 2H, C<sub>3</sub>–H), 3.20 (br h, 1H, C<sub>4</sub>–H), 4.02 (t, *J* = 7.05 Hz, C<sub>2</sub>–H), 4.47 (d, 1H, *J*<sub>4a,5a</sub> = 8.0 Hz, C<sub>5</sub>–H), 6.8–7.4 (m, 3H, Ar–H), 7.65 (m, 1H, Ar–H). Anal. Calcd for C<sub>10</sub>H<sub>13</sub>NO<sub>2</sub>·HCl (215.5): C, 67.03; H, 7.27; N, 7.82. Found: C, 66.70; H, 7.34; N, 7.63.

7. *General procedure for synthesis of 4*: A mixture of *cis*-acetamido alcohol **6a–f** (2.5 mmol) MeOH (30 mL) and 10% aqueous NaOH (20 mL) was refluxed on a steam bath for 12 h. The solution was cooled and solvent MeOH removed under reduced pressure. The solid product on cooling was filtered, washed with H<sub>2</sub>O, dried, and crystallized with CHCl<sub>3</sub>–*n*-C<sub>6</sub>H<sub>12</sub>. For example, *cis*-4-amino-2,3,4,5-tetrahydro-1-benzoxepin-5-ol hydrochloride (**4d**) yield 90%; mp 278 °C; IR (free base) 3335, 3275, 1000, 960, 950, and 660/cm; <sup>1</sup>H NMR: δ 2.08 (br h, 3H, OH, NH<sub>2</sub> exchangeable by D<sub>2</sub>O), 2.78 (m, 2H, C<sub>3</sub>–H), 3.25 (br h, 1H, C<sub>4</sub>–H), 4.02 (t, *J* = 7.05 Hz, C<sub>2</sub>–H), 4.82 (d, 1H, *J*<sub>4a,5e</sub> = 1.5 Hz, C<sub>5</sub>–H), 6.8–7.5 (m, 4H, Ar–H). Anal. Calcd for C<sub>10</sub>H<sub>13</sub>NO<sub>2</sub>·HCl (215.5): C, 67.03; H, 7.27; N, 7.82. Found: C, 66.70; H, 7.60; N, 7.54.